Our Study on Türkiye's First Acemetacin Extended-Release Generic Product Featured in the 'European Journal of Applied Sciences'!
Developed at our Santa Farma Pharmaceuticals R&D Center as Türkiye's first acemetacin extended-release generic product, the results of the in-vivo bioequivalence study conducted by our Clinical Trials Department for the Extended-Release Hard Capsule have been published in the European Journal of Applied Sciences.
The successful completion of the in-vivo bioequivalence study for our product containing the active ingredient acemetacin, along with its publication in an international scientific journal, once again demonstrates our scientific competence, innovative approach, and commitment to global quality standards.
This publication stands as a tangible reflection of not just our achievement in product development, but also our Clinical Trials Department's commitment to operating in line with up-to-date regulations, ethical principles, and scientific excellence.
As Santa Farma, we continue to transform our R&D strength into scientific outputs, enhance our visibility on international platforms, and successfully represent the Turkish pharmaceutical industry in the global arena.
